Loading…
← CockpitCompetitor Analysis › TATVA.NS Tatva Chintan Pharma Chem LimitedOpen in the cockpit ↗

Tatva Chintan Pharma Chem LimitedTATVA.NSCompetitor analysis, valuation and peers

India · INR·Chemicals›Chemicals: Specialty
Momentum neutral 51
Mkt cap
$398M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$2.59M
20-day average traded
Fwd P/E
48.5×
forward earnings
ROIC−WACC
-8.9 pp
WACC 15.6%
Hurdle
n/a
no reverse DCF
Next earnings
76 days
21 Jan 2027
Close · INR₹1,606
1D-3.6%
1W-2.3%
1M-19.4%
3M-7.2%
6M+17.9%
YTD+20.4%
1Y+18.1%
ATR %6.3%
Beta1.05
52w lowhigh24.0% off high

What Tatva Chintan Pharma Chem does

Employees: 1,097

Tatva Chintan Pharma Chem at a glance

Size Tatva Chintan Pharma Chem (TATVA.NS) is an India Materials company (Chemicals: Specialty) with a market value of $398M, the 942nd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,606 on 6 Nov 2026.

Performance Over six months the shares gained 17.9%, against -24.4% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 49.7% over the last twelve months (peer median +4.1%); the operating margin is 13.3% (peer median 7.3%).

Valuation It trades at 48.5× forward earnings against a peer median of 22.4× (most expensive of 9).

Capital Return on invested capital runs 8.9 points below its cost of capital (15.6% WACC).

Next results Next results expected around 21 Jan 2027 (exchange calendar; dates can move).

Relative performance

7510012515011 May 202611 Aug 20266 Nov 2026TATVA.NS 119Peer median 75
Six months, rebased to 100: Tatva Chintan Pharma Chem against the median of its 20 peers (local-currency closes).

Tatva Chintan Pharma Chem financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹6.50B₹5.03B₹3.82B₹3.93B₹4.23B
Revenue growth—+32%-3%-7%—
Gross profit₹2.48B₹1.07B₹464M₹725M₹928M
EBITDA₹1.27B₹1.00B₹374M₹678M₹675M
Net income₹629M₹421M₹57.1M₹304M₹455M
Free cash flown/a-₹841M-₹524M-₹337M-₹1.78B
Capital expendituren/a₹1.14B₹763M₹1.29B₹2.03B
Total debt₹1.70B₹1.20B₹364M₹143M₹1.70B

Quarterly statements and history in the cockpit →

Tatva Chintan Pharma Chem competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%001358001335RYAMTROX21084722688357VISHNU300631171000665030128100275330072130105940971718TATVA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Tatva Chintan Pharma Chem is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×RYAM4722688357VISHNU3006311710006650002753TATVA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tatva Chintan Pharma Chem is the large dot.

Tatva Chintan Pharma Chem competitors and peer comparison

How Tatva Chintan Pharma Chem compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tatva Chintan Pharma Chem against its 20 peers (data as of 6 Nov 2026)
MeasureTATVA.NSPeer medianRank in peer set
1-month return-19.4%-12.1%5th lowest of 21
6-month return+17.9%-24.4%3rd highest of 20
Distance from 52-week high-24.0%-38.6%5th highest of 21
Revenue growth (TTM)+49.7%+4.1%highest of 21
Operating margin13.3%7.3%5th highest of 21
Forward P/E48.5×22.4×most expensive of 9
ROIC minus cost of capital-8.9 pp-3.7 pp2nd lowest of 19
EV / EBITDA30.9×16.2×3rd most expensive of 8
Net debt / EBITDA1.2×3.4×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tatva Chintan Pharma Chem TATVA.NSIndia$398M+18%+50%13%48.5×n/an/a
Shaoxing Xingxin New Material 001358.SZChina$398M-25%-8%9%n/an/an/a
Trust Chem 001335.SZChina$399M-39%+5%7%n/a25.0%+5.6%
Rayonier Advanced Materials RYAMUnited States$399M-36%+2%0%16.5×32.2%+1.8%
Tronox TROXUnited States$401M-72%+4%-3%n/an/an/a
Nantex Industry 2108.TWTaiwan$401M0%-3%13%n/an/an/a
Qualipoly Chemical 4722.TWTaiwan$402M-32%-4%8%24.7×n/an/a
Luoyang Jianlong Micro-nano New Materials 688357.SSChina$393M-28%+12%13%25.0×8.5%+13.2%
Vishnu Chemicals VISHNU.NSIndia$393M-8%+14%13%20.0×n/an/a
Jiangsu Jiuwu Hi-Tech 300631.SZChina$389M-26%+15%10%30.1×17.1%+3.5%
Oriental Union Chemical 1710.TWTaiwan$406M+22%-13%-4%16.0×n/an/a
KPIC 006650.KSSouth Korea$387M-53%+11%4%8.7×-17.8%+12.2%
Shandong Keyuan Pharmaceutical 301281.SZChina$387M+9%+33%15%n/an/an/a
Shanxi Yongdong Chemistry Industry 002753.SZChina$386M-19%+18%1%27.3×n/an/a
Jiangsu Yida Chemical 300721.SZChina$386M-22%+40%2%n/a12.8%+9.7%
Steamhouse India STEAMHOUSE.NSIndia$384Mn/a+24%14%n/an/an/a
Aduro Clean Technologies ACT.TOCanada$383M-15%-44%-13,483%n/an/an/a
Jinsanjiang (Zhaoqing) Silicon Material 301059.SZChina$381M-24%+27%20%n/a8.5%+18.0%
Koatsu Gas Kogyo 4097.TJapan$416M+8%+1%6%n/a-9.1%+5.1%
Danhua Chemical Technology 600844.SSChina$379M-25%-6%-9%n/an/an/a
China Man-Made Fiber 1718.TWTaiwan$377M+43%-12%38%n/a-4.6%+11.4%

Questions

Which companies are Tatva Chintan Pharma Chem's closest peers?
The cockpit's peer set: Shaoxing Xingxin New Material (001358.SZ), Trust Chem (001335.SZ), Rayonier Advanced Materials (RYAM), Tronox (TROX), Nantex Industry (2108.TW), Qualipoly Chemical (4722.TW), Luoyang Jianlong Micro-nano New Materials (688357.SS), Vishnu Chemicals (VISHNU.NS).
Is Tatva Chintan Pharma Chem expensive compared with its peers?
On forward p/e it trades at 48.5× against a peer median of 22.4×, most expensive of 9 in its peer set.
How has Tatva Chintan Pharma Chem stock performed?
Over six months to 6 Nov 2026 the shares returned +17.9% against -24.4% for the median peer; over one year +18.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.